CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) represent the therapeutic mainstay for patients with hormone receptor-positive, HER2-negative advanced breast cancer (HR + /HER2-ABC). Here, NR4A1 is linked to breast cancer.